QI
KPTI icon

QS Investors’s Karyopharm Therapeutics KPTI Stock Holding History

QS Investors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,927
Closed -$422K – 1224
2020
Q3 		$422K Sell
1,927
-7,810
-80% -$1.91M 0.01% 780
2020
Q2 		$2.77M Sell
9,737
-16
-0.2% -$4.73K 0.04% 367
2020
Q1 		$2.81M Hold
9,753
– – 0.04% 315
2019
Q4 		$2.74M Buy
+9,753
New +$2.12M 0.03% 480

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

QS Investors's KPTI Position: Q4 2020 in Review

QS Investors sold out of Karyopharm Therapeutics (KPTI) in Q4 2020, closing a stake of 1,927 shares — an estimated $422K sold.

QS Investors first reported a position in KPTI in Q4 2019 and held it in 4 quarters. The position peaked at $2.81M in Q1 2020. 168 funds tracked by Wall St. Rank hold KPTI as of Q4 2020.

  • QS Investors reported no remaining Karyopharm Therapeutics position as of Q4 2020 after selling out during the quarter.
  • QS Investors sold 1,927 Karyopharm Therapeutics shares in Q4 2020, an estimated $422K.
  • QS Investors first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 4 quarters.
  • QS Investors's Karyopharm Therapeutics position peaked at $2.81M in Q1 2020.
  • 168 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2020.

Based on QS Investors's 13F filing for Q4 2020, filed 10 Feb 2021.